A step forward in the treatment of myelofibrosis

A step forward in the
treatment of myelofibrosis
Learn more about the first
and only medication proven to
specifically treat intermediate
or high-risk myelofibrosis
Please see Important Safety Information on
pages 18 and 19 and accompanying Full Prescribing
Information, which includes a more complete
discussion of the risks associated with Jakafi.
www.jakafi.com
Jakafi® is a prescription medicine used to treat people with
intermediate or high-risk myelofibrosis, including primary
myelofibrosis, post–polycythemia vera myelofibrosis, and
post–essential thrombocythemia myelofibrosis.
Table of contents
Since I started on Jakafi,
my spleen is significantly
reduced, and I‘ve noticed a
decrease in my symptoms.
—Dan
Living with myelofibrosis since 2009
Living with myelofibrosis .........................................................4
What is myelofibrosis?.............................................................6
Signs and symptoms of myelofibrosis.....................................8
Possible causes of myelofibrosis ........................................... 10
How does Jakafi work?.......................................................... 13
What are the possible benefits of Jakafi?.............................. 14
Important Safety Information on Jakafi ................................. 18
What are the side effects of taking Jakafi?............................20
How do I take Jakafi?.............................................................22
What to expect while taking Jakafi........................................24
How can I take an active role in my treatment?.....................26
Glossary.................................................................................28
Notes .....................................................................................31
The core symptoms studied with Jakafi were
abdominal discomfort, early feeling of fullness,
pain under the left ribs, itching, night sweats, and
bone/muscle pain. Individual results may vary.
Please see Important Safety Information on pages 18 and 19
and accompanying Full Prescribing Information, which includes
a more complete discussion of the risks associated with Jakafi.
2
www.jakafi.com
Living with intermediate or
high-risk myelofibrosis
If you or someone close to you has been diagnosed with
intermediate or high-risk myelofibrosis (MY-ah-lo-fye-BRO-sis),
know that you are not alone. There are thousands of people
living with this disease, and now there is a medication available
that has been proven to specifically treat this condition.
This guide was written to help you understand more about
this condition and treatment with Jakafi (JAK-ah-fye). You will find
information on these topics, as well as a list of helpful resources.
This guide will also provide you with tips on how to talk to your
doctor about managing your condition while taking Jakafi.
Not actual patients.
It is not known if Jakafi is safe or effective in children. It is not indicated
for children.
Jakafi is an oral prescription medicine used to treat people
with intermediate or high-risk myelofibrosis. If you have
intermediate or high-risk myelofibrosis, it means that you
have 1 or more of these risk factors:
Age greater than 65
Elevated blasts
Presence of certain symptoms (undeveloped blood cells)
Anemia
Platelets below a certain level
Elevated white blood cells
Need for blood transfusions
4
www.jakafi.com
Before and during treatment, it is important to take an active
role in your care. Learning more about your condition and asking
questions will help you make the most of treatment with Jakafi.
You will notice that some words are green and bold
within this brochure. These terms are explained in
the glossary (pages 28 to 30).
Please see Important Safety Information on pages 18 and 19
and accompanying Full Prescribing Information, which includes
a more complete discussion of the risks associated with Jakafi.
Myelofibrosis is a bone marrow condition that is part of a
group of diseases called “myeloproliferative neoplasms“
(MY-ah-lo-pro-LIF-er-uh-tiv NEE-o-plaz-uhms). Myelofibrosis
is also known as a bone marrow cancer or blood cancer.
Your doctor may or may not have called myelofibrosis a cancer.
We understand that hearing the word “cancer“may be scary,
so it is important to remember that the seriousness of each
person’s condition is different. Be sure to speak to your doctor
about your specific case. On pages 26 and 27, you will find
helpful tips for talking to your doctor.
How myelofibrosis develops
Bone marrow is where blood cells are made. People with
myelofibrosis have a defect in their bone marrow that causes
an imbalance of blood cells (too many or too few).
Generally, people with myelofibrosis have too many or too few
Red blood cells
White blood cells
Platelets
An imbalance of these blood cells may cause symptoms
and complications.
Enlarged spleen and other symptoms
Myelofibrosis can cause an enlarged spleen and various
symptoms. Some other symptoms you may or may not
recognize as related to myelofibrosis include abdominal
discomfort, early feeling of fullness, pain under left ribs, itching,
night sweats, and bone/muscle pain. These symptoms will be
discussed in more detail on pages 8 and 9.
6
www.jakafi.com
These are not all of the symptoms of myelofibrosis. Please talk to
your doctor about any symptoms you are having.
Myelofibrosis can also lead to serious complications, such as
blood clotting, bleeding, and infection.
Facts about myelofibrosis
Myelofibrosis is 1 of a group of disorders called
”myeloproliferative neoplasms,” also known as MPNs
Myelofibrosis is sometimes a person’s first MPN.
This is called ”primary myelofibrosis”
– In other cases, it can develop from other MPNs,
such as polycythemia vera (PV) or essential
thrombocythemia (ET)
Depending on your risk factors for myelofibrosis,
your doctor will consider your condition to be low,
intermediate, or high risk
Myelofibrosis is the rarest and most serious MPN
– Approximately 16,000 to 18,500 people in the
United States are diagnosed with myelofibrosis
– It is estimated that 80% to 90% of people with
myelofibrosis have intermediate or high-risk myelofibrosis
Please see Important Safety Information on pages 18 and 19
and accompanying Full Prescribing Information, which includes
a more complete discussion of the risks associated with Jakafi.
Understanding
Myelofibrosis
What is myelofibrosis?
Understanding
Myelofibrosis
Signs and symptoms of myelofibrosis
New blood cells are usually made in the bone marrow. But
because the bone marrow does not work as it should in people
with myelofibrosis, the spleen also makes new blood cells and
stores many of them. This can cause the spleen to get bigger.
People with myelofibrosis may also have other symptoms, such as
Itching
Night sweats
Bone/muscle pain
Many people with myelofibrosis have an enlarged spleen.
This is a key sign of the disease.
It is important to tell your doctor about any symptoms you are
having, even if they do not bother you. There may be a treatment
that can help.
Spleen growth varies in people with myelofibrosis,
but any degree of spleen growth is not normal.
Spleen size is known to increase over time in
people with myelofibrosis.
spleen
As the spleen makes new blood cells, it can continue to grow in size, as seen in
the picture above.
An enlarged spleen can cause symptoms, such as
Abdominal discomfort
Early feeling of fullness
Pain under the left ribs
8
www.jakafi.com
How myelofibrosis can change over time
Myelofibrosis is a chronic condition, meaning it lasts a long time
and does not go away, and there are many things that can affect the
course of your disease.
There are different factors that your doctor may use to determine
your disease outlook. You are considered to have intermediate or
high-risk myelofibrosis if you have or have had 1 or more of these
risk factors at any time: Age greater than 65, presence of certain
symptoms, anemia, elevated white blood cells, elevated blasts,
platelets below a certain level, or a need for blood transfusions
unrelated to drug therapy.
Myelofibrosis develops differently in each person. In some people,
the disease can get worse over time and can lead to a more
enlarged spleen and more severe symptoms.
Therefore, it is important to speak to your doctor about the severity
of your disease and which treatment may be right for you.
Please see Important Safety Information on pages 18 and 19
and accompanying Full Prescribing Information, which includes
a more complete discussion of the risks associated with Jakafi.
Possible causes of myelofibrosis
Myelofibrosis is a complex condition, and researchers are still trying
to discover its exact cause. However, these researchers now think
that 1 cause is when proteins that communicate within blood
cells send too many messages. These proteins are called “JAKs“
(Janus kinases), and the messages they send are called “signals.”
When they are signaling normally, JAKs help your body make the
right number of blood cells. When JAKs send too many signals,
they cause the body to make the wrong number of blood cells.
This chain of events is called “overactive JAK signaling.”
A JAK2 mutation is present in about 50% to 60% of people
with myelofibrosis. Because of this, your doctor may test to see
if you have a JAK2 mutation. This can help him or her confirm a
diagnosis of myelofibrosis.
Overactive JAK signaling in the blood-forming cells
Cell
membrane
Having the wrong number of blood cells may lead to increased
blood clotting, bleeding, anemia, or an increased risk of infection.
Overactive
signaling
Overactive JAK signaling may also lead to an
enlarged spleen and myelofibrosis symptoms.*
JAK
How JAK signaling can become overactive
JAK signaling can become overactive in many ways. One of these
ways is by a JAK2 mutation. However, even people without a
JAK2 mutation are believed to have overactive JAK signaling.
*The core symptoms studied with Jakafi were abdominal discomfort, early feeling
of fullness, pain under the left ribs, itching, night sweats, and bone/muscle pain.
10 www.jakafi.com
All people with myelofibrosis are believed to have
overactive JAK signaling, even if they do not
have a JAK2 mutation.
Please see Important Safety Information on pages 18 and 19
and accompanying Full Prescribing Information, which includes
a more complete discussion of the risks associated with Jakafi.
Jakafi is the first and only medication
approved to treat intermediate or
high-risk myelofibrosis
It is not known if Jakafi is safe or effective in children. It is not indicated
for children.
Indication
Jakafi is a prescription medicine used to treat people with
intermediate or high-risk myelofibrosis, including primary
myelofibrosis, post–polycythemia vera myelofibrosis, and
post–essential thrombocythemia myelofibrosis.
Jakafi can cause serious side effects including:
Low blood counts: Jakafi may cause your platelet, red blood
cell, or white blood cell counts to be lowered. Tell your healthcare
provider right away if you experience unusual bleeding, bruising,
fatigue, shortness of breath, or a fever. Your healthcare provider
will perform blood tests to check your blood counts before you
start Jakafi and regularly during your treatment. Your healthcare
provider may change your dose of Jakafi or stop your treatment
based on the results of your blood tests.
12 www.jakafi.com
Jakafi is designed to target JAKs (Janus kinases). By doing so, Jakafi
decreases overactive JAK signaling.
Jakafi works in different types of myelofibrosis. It was studied
in people
With or without a JAK2 mutation
With primary myelofibrosis
With secondary myelofibrosis (post–polycythemia
vera myelofibrosis or post–essential thrombocythemia
myelofibrosis)
A new era in myelofibrosis treatment
Before Jakafi, no therapies were approved to specifically treat
myelofibrosis. Instead, doctors used medicines approved for
other diseases to try and help control the signs and symptoms
of myelofibrosis.
With Jakafi, a medication is available that is approved to specifically
treat intermediate or high-risk myelofibrosis by targeting JAKs.
In 1 study, close to half (42%) of all people taking Jakafi had
a 35% or greater reduction in spleen size. Also in that study,
almost half (46%) of people taking Jakafi had their Total Symptom
Score (TSS) improved by 50% or more. The TSS represents a
group of symptoms that were measured over a 6-month period and
consisted of abdominal discomfort, early feeling of fullness, pain
under the left ribs, itching, night sweats, and bone/muscle pain.
Please see Important Safety Information on pages 18 and 19
and accompanying Full Prescribing Information, which includes
a more complete discussion of the risks associated with Jakafi.
Treatment
With Jakafi
Not actual patients.
How does Jakafi (JAK-ah-fye) work?
Treatment
With Jakafi
What are the possible benefits of Jakafi?
Jakafi has been studied in more than 300 people with intermediate
or high-risk myelofibrosis. These studies were designed to see
if Jakafi helped reduce spleen size and improve symptoms. The core
symptoms studied with Jakafi were abdominal discomfort, early
feeling of fullness, pain under the left ribs, itching, night sweats,
and bone/muscle pain. Jakafi was tested in 2 separate studies
against placebo (sugar pill) and other medicines, such as
hydroxyurea and glucocorticoids.
Jakafi can cause serious side effects including
Infection: You may be at risk for developing a serious infection
while taking Jakafi. Tell your healthcare provider if you develop
symptoms such as chills, nausea, vomiting, aches, weakness,
fever, or painful skin rash or blisters.
Jakafi provided reductions in spleen size
Jakafi in people with anemia
Overall, more people in the study taking Jakafi required red
blood cell transfusions than people taking placebo.
Spleen size before Jakafi
Reduced spleen size with Jakafi
Jakafi may be prescribed in people who test positive
or negative for a JAK2 mutation.
In this study, people who developed anemia while taking
Jakafi experienced reductions in spleen size and improvements
in symptoms that were similar to people who did not develop
anemia while on therapy.
The change in spleen size shown is based on the results of a study that looked
at spleen size before people took Jakafi and again 6 months after starting Jakafi.
The study assessed whether a person had at least a 35% reduction in spleen size.
Individual results may vary.
Spleen size is known to increase in people with
myelofibrosis. In 2 studies, people taking Jakafi had
a greater reduction in spleen size compared with
people who did not take this treatment.
14 www.jakafi.com
On average, when treatment was started with Jakafi, people‘s
hemoglobin levels lowered. After several weeks of continued
treatment, hemoglobin gradually increased to a new, steady level
that was still lower than at the beginning of treatment.
On page 20, you will find more information about possible
blood-related side effects with Jakafi. You should discuss these
side effects with your healthcare provider to help understand
what they may mean to your specific condition.
Please see Important Safety Information on pages 18 and 19
and accompanying Full Prescribing Information, which includes
a more complete discussion of the risks associated with Jakafi.
Jakafi provided improvements in
myelofibrosis symptoms
Symptoms are known to get worse in people with myelofibrosis.
Researchers measured the effect Jakafi had on the following core
symptoms, which, when combined, make up the Total Symptom
Score (TSS):
Spleen-related
Abdominal discomfort
Early feeling of fullness
Pain under the left ribs
Non–spleen-related
Some of the side effects with Jakafi
Common side effects seen with Jakafi are dizziness and headache.
These are not all the possible side effects of Jakafi. Ask your
healthcare provider or pharmacist for more information. Tell your
healthcare provider about any side effect that bothers you or that
does not go away.
Itching
Night sweats
Bone/muscle pain
When combined, improvements in each of these symptoms led
to a better TSS in people taking Jakafi, compared with people not
taking Jakafi.
Almost half of people taking Jakafi had their group of symptoms
improve by 50% or more over a 6-month period.
In people who did not take Jakafi, these symptoms often got worse.
If you experience blood-related side effects, your
doctor may have to raise or lower your dose of
Jakafi or temporarily stop your treatment.
“I didn't know what was causing some of my symptoms.
My doctor told me that my early feeling of fullness, itching,
night sweats, and bone/muscle pain may be caused
by myelofibrosis.”
—Susan
Living with myelofibrosis
Please see Important Safety Information on pages 18 and 19
and accompanying Full Prescribing Information, which includes
a more complete discussion of the risks associated with Jakafi.
16 www.jakafi.com
Important Safety Information on Jakafi
Infection: You may be at risk for developing a serious infection
while taking Jakafi. Tell your healthcare provider if you develop
symptoms such as chills, nausea, vomiting, aches, weakness,
fever, or painful skin rash or blisters.
The most common side effects of Jakafi include
dizziness and headache.
These are not all the possible side effects of Jakafi. Ask your
healthcare provider or pharmacist for more information. Tell your
healthcare provider about any side effect that bothers you or that
does not go away.
Jakafi can cause serious side effects including:
Low blood counts: Jakafi may cause your platelet, red blood
cell, or white blood cell counts to be lowered. Tell your healthcare
provider right away if you experience unusual bleeding, bruising,
fatigue, shortness of breath, or a fever. Your healthcare provider will
perform blood tests to check your blood counts before you start
Jakafi and regularly during your treatment. Your healthcare provider
may change your dose of Jakafi or stop your treatment based on
the results of your blood tests.
Before taking Jakafi, tell your healthcare provider about all the
medications, vitamins, and herbal supplements you are taking and
all your medical conditions, including if you have an infection, have
or had liver or kidney problems, are on dialysis, or have any other
medical condition. Talk to your healthcare provider before drinking
grapefruit juice while taking Jakafi.
Women should not take Jakafi while pregnant or planning to
become pregnant, or if breast-feeding.
Please see accompanying Full Prescribing Information, which includes
a more complete discussion of the risks associated with Jakafi.
18 www.jakafi.com
Side Effects
With Jakafi
Not actual patient.
What are the side effects of taking Jakafi?
Possible blood-related side effects
Jakafi works in blood cells by targeting JAKs (Janus kinases),
which control blood production. In people with myelofibrosis,
JAKs become overactive, sending too many signals. While Jakafi
reduces overactive JAK signaling, it may also cause certain blood
counts to become lower.
Because of this, your doctor will continue to check your blood
counts to evaluate any blood-related side effects, such as
Side Effects
With Jakafi
Thrombocytopenia (throm-bo-sye-toe-PEE-nee-uh):
A condition in which a person has a low number of platelets.
This may cause problems with blood clotting, including
bruising and bleeding
Anemia (uh-NEE-mee-uh): A condition in which a person has
a low number of red blood cells. This may cause tiredness
(fatigue), a feeling of weakness, and shortness of breath
Neutropenia (new-truh-PEE-nee-uh): A condition in which a
person has a low number of white blood cells. Neutropenia
may increase the risk for infections
In studies, blood-related side effects caused 1% or less of
people to stop treatment. If you experience any of these side
effects, your doctor may have to raise or lower your dose of
Jakafi or temporarily stop your treatment.
Possible non–blood-related side effects
In a study, non–blood-related side effects experienced by people
taking Jakafi included bruising, dizziness, and headache.
Some people in the study stopped treatment. A similar
percentage of people (about 11%) stopped their treatment
whether they were taking Jakafi or placebo.
These are not all of the possible side effects associated with
Jakafi. Ask your healthcare team for more information.
Tell your doctor about any side effects
you experience while taking Jakafi.
Please see Important Safety Information on pages 18 and 19
and accompanying Full Prescribing Information, which includes
a more complete discussion of the risks associated with Jakafi.
20 www.jakafi.com
How do I take Jakafi?
Take Jakafi twice a day as directed by your doctor
Jakafi is a pill that you take twice a day, at about the same
time each day. You can take Jakafi with or without food.
If you miss a dose, take your next one as scheduled.
Do not take an additional dose.
Before taking Jakafi
Before taking Jakafi, tell your healthcare provider about all the
medications, vitamins, and herbal supplements you are taking.
Especially tell your doctor if you take medicine for fungal
infections, bacterial infections, or HIV/AIDS.
Also tell your doctor about all of your medical conditions, including
if you have an infection, have or have had liver or kidney problems,
or are on dialysis. Jakafi should be taken after your dialysis. Tell
your doctor if you have any other medical conditions. Talk to your
healthcare provider before drinking grapefruit juice while taking
Jakafi. Women should not take Jakafi while pregnant or planning to
become pregnant, or if breast-feeding.
Bottles and tablets shown are not actual size and are not proportional to each other.
If you take too much Jakafi, call your healthcare provider or go
to the nearest hospital emergency department right away.
Take the bottle of Jakafi with you.
Not actual patient.
Please see Important Safety Information on pages 18 and 19
and accompanying Full Prescribing Information, which includes
a more complete discussion of the risks associated with Jakafi.
22 www.jakafi.com
How to Take Jakafi
There are different strengths of Jakafi: 5 mg, 10 mg, 15 mg,
20 mg, and 25 mg. Make sure you take your dose exactly
as your doctor prescribes.
What to expect while taking Jakafi
As mentioned earlier, Jakafi may cause certain blood counts to
become lower. Therefore, your doctor will monitor your blood
count levels while you are taking Jakafi.
Before you begin treatment: Your doctor will perform a
complete blood count (CBC). The results of your test will
determine which dose of Jakafi is right for you.
During treatment: Your doctor will check your blood cell
counts regularly to make sure they don’t become too low.
Why is it important to keep taking Jakafi?
Even if you start feeling better, you should still continue to
take Jakafi as your doctor prescribes. Once treatment with
Jakafi stops, the spleen is expected to get bigger again and
symptoms are expected to return in as little as 1 week.
If you are having any side effects, tell your doctor. Do not
stop taking Jakafi without speaking to him or her first.
Depending on how you’re responding to Jakafi: Your doctor
may raise or lower your dose to help maintain appropriate blood
count levels and/or treat your condition. In some instances, your
doctor may have to temporarily stop treatment with Jakafi.
How to Take Jakafi
Your doctor may tell you to stop taking Jakafi if, after 6 months, you
don‘t see any reduction in spleen size or improvement in symptoms.
If you can‘t take Jakafi by mouth: Jakafi may also be given through
certain nasogastric tubes. A nasogastric tube delivers the medicine
directly to your stomach. Your healthcare provider will decide if you
can take Jakafi in this manner. Ask your healthcare provider to give
you specific instructions on how to properly take Jakafi through a
nasogastric tube.
Take Jakafi twice a day as directed by your doctor
It is important to continue taking Jakafi every day, just as your
doctor prescribes. Jakafi is a long-term treatment.
24 www.jakafi.com
It is important to stay on Jakafi as directed by your
doctor, so he or she can best manage your condition.
Please see Important Safety Information on pages 18 and 19
and accompanying Full Prescribing Information, which includes
a more complete discussion of the risks associated with Jakafi.
How can I take an active role
in my treatment?
Topics to discuss with your doctor
There are many things you can learn about myelofibrosis and
Jakafi. The more you know, the more you can play an active role
in your care.
One way you can take an active role is to set treatment goals.
Discuss with your doctor what to expect while taking Jakafi,
and make a plan for the future. Also, be sure to always keep
an open dialogue with your doctor.
Keep track of how you feel
Always tell your doctor how you’re feeling. Be sure to report any
new symptoms or current symptoms that may be getting worse.
The only way your doctor can properly treat your disease is if he
or she is fully aware of how you’re feeling.
You can use the Notes section on page 31 to keep track of
how you feel.
Ask questions, such as
How severe is my disease?
What can I do to best manage my disease?
Is Jakafi right for me?
How long will I take Jakafi?
How will I feel while taking Jakafi?
What should I look out for when taking Jakafi?
Are there any foods or medications that I should avoid
while taking Jakafi?
Not actual patient.
Please see Important Safety Information on pages 18 and 19
and accompanying Full Prescribing Information, which includes
a more complete discussion of the risks associated with Jakafi.
26 www.jakafi.com
Glossary
Anemia: A condition in which a person has a low number of red
blood cells.
Blasts: Undeveloped, immature cells that develop into mature
blood cells.
Bone marrow: Where blood cells are made. Bone marrow
is soft tissue found inside some bones, such as the hip and
thigh bones, that contains immature cells called “stem cells.”
These stem cells can develop into red blood cells, white blood
cells, or platelets.
Chronic: Conditions that last a long period of time.
Complete blood count (CBC): A blood test that measures
different cells and other elements in your blood. The results of
a CBC give doctors a better picture of overall health.
Essential thrombocythemia (ET): A disease in which the bone
marrow produces too many platelets. Having too many platelets
can cause symptoms and complications. People with ET often
do not have symptoms. They may, however, be prone to blood
clots and other complications.
Hemoglobin: The part of the red blood cell that carries oxygen.
Myeloproliferative neoplasms (MPNs): A group of blood
conditions that involve an imbalance in the number of blood
cells being made. Myelofibrosis (including primary myelofibrosis,
post–polycythemia vera myelofibrosis, and post–essential
thrombocythemia myelofibrosis), essential thrombocythemia,
and polycythemia vera are MPNs. They are sometimes called
blood cancers, bone marrow cancers, or bone marrow disorders
(because blood cells are made in your bone marrow).
Neutropenia: A condition in which a person has a low number
of white blood cells.
Platelets: Small cell fragments that help stop bleeding and aid
in healing.
Polycythemia vera (PV): A disease in which the bone marrow
produces too many blood cells, especially red blood cells. These
cells function normally, but there are too many of them. Platelets
and white blood cells may also be overproduced.
Post–essential thrombocythemia myelofibrosis:
Myelofibrosis that develops from essential thrombocythemia.
Post–polycythemia vera myelofibrosis: Myelofibrosis that
develops from polycythemia vera.
JAKs (Janus kinases): Proteins that exist in blood cells.
Mutation: A small change in DNA that causes proteins to act
differently than they are supposed to.
Please see Important Safety Information on pages 18 and 19
and accompanying Full Prescribing Information, which includes
a more complete discussion of the risks associated with Jakafi.
Glossary
28 www.jakafi.com
Glossary (continued)
Notes
Primary myelofibrosis: Myelofibrosis that did not develop from
either polycythemia vera or essential thrombocythemia.
Please use this section to write down any questions or thoughts
you may wish to share with your healthcare team.
Proteins: Natural substances that exist in cells. Proteins are vital
players in all of the cellular activities in the body.
Red blood cells: Cells that deliver oxygen throughout the body.
These cells also remove waste products from the body‘s tissues.
Secondary myelofibrosis: Myelofibrosis that develops from
polycythemia vera or essential thrombocythemia.
Spleen: An organ located above your stomach and under the left
ribs. It is approximately the size of a fist. The spleen fights infection
and stores red blood cells and platelets. The spleen filters blood,
destroys old and damaged cells, and contains white blood cells
that fight germs.
Thrombocytopenia: A condition in which a person has a low
number of platelets.
White blood cells: Blood cells that help fight infection.
Glossary
Please see Important Safety Information on pages 18 and 19
and accompanying Full Prescribing Information, which includes
a more complete discussion of the risks associated with Jakafi.
30 www.jakafi.com
A step forward in the treatment of myelofibrosis
Myelofibrosis is a serious chronic condition that develops from a defect in
the bone marrow. Myelofibrosis can cause an enlarged spleen and various
symptoms. There may be a treatment that can help.
Jakafi is the first and only prescription medication proven to specifically treat
intermediate or high-risk myelofibrosis.
Jakafi reduces the enlarged spleen and helps improve the symptoms*
of myelofibrosis
Jakafi can cause serious side effects, including low blood counts and
an increased risk of infection. In a study, non–blood-related side effects
were usually mild and included bruising, dizziness, and headache
Visit www.jakafi.com/brochure for more information on
Jakafi and myelofibrosis, plus valuable educational resources.
Visit www.IncyteCARES.com or call 1-855-4-Jakafi (855-452-5234)
to get connected to support from Incyte.
You are encouraged to report negative side effects of prescription drugs
to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
*People taking Jakafi had an improvement in a group of symptoms. The group of symptoms that
Jakafi has been proven to improve is abdominal discomfort, early feeling of fullness, pain under
the left ribs, itching, night sweats, and bone/muscle pain.
Please see Important Safety Information on
pages 18 and 19 and accompanying Full Prescribing
Information, which includes a more complete
discussion of the risks associated with Jakafi.
Jakafi is a registered trademark of Incyte Corporation.
© 2012, Incyte Corporation. All rights reserved. RUX-1013 06/12